Huntsman DG - Search Results

1

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study.

Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group; Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. Köbel M, et al. Among authors: huntsman dg. Br J Cancer. 2014 Dec 9;111(12):2297-307. doi: 10.1038/bjc.2014.567. Epub 2014 Oct 30. Br J Cancer. 2014. PMID: 25349970 Free PMC article.

2

Identification of germ-line E-cadherin mutations in gastric cancer families of European origin.

Gayther SA, Gorringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C. Gayther SA, et al. Cancer Res. 1998 Sep 15;58(18):4086-9. Cancer Res. 1998. PMID: 9751616

3

Familial gastric cancer: overview and guidelines for management.

Caldas C, Carneiro F, Lynch HT, Yokota J, Wiesner GL, Powell SM, Lewis FR, Huntsman DG, Pharoah PD, Jankowski JA, MacLeod P, Vogelsang H, Keller G, Park KG, Richards FM, Maher ER, Gayther SA, Oliveira C, Grehan N, Wight D, Seruca R, Roviello F, Ponder BA, Jackson CE. Caldas C, et al. Among authors: huntsman dg. J Med Genet. 1999 Dec;36(12):873-80. J Med Genet. 1999. PMID: 10593993 Free PMC article. Review.

4

CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer.

Pharoah PD, Oliveira C, Machado JC, Keller G, Vogelsang H, Laux H, Becker KF, Hahn H, Paproski SM, Brown LA, Caldas C, Huntsman D. Pharoah PD, et al. Int J Cancer. 2002 Sep 10;101(2):196-7. doi: 10.1002/ijc.10590. Int J Cancer. 2002. PMID: 12209998 Free article.

5

Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level.

Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. Alkushi A, et al. Int J Gynecol Pathol. 2004 Apr;23(2):129-37. doi: 10.1097/00004347-200404000-00007. Int J Gynecol Pathol. 2004. PMID: 15084841

6

Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma.

Makretsov NA, Huntsman DG, Nielsen TO, Yorida E, Peacock M, Cheang MC, Dunn SE, Hayes M, van de Rijn M, Bajdik C, Gilks CB. Makretsov NA, et al. Among authors: huntsman dg. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6143-51. doi: 10.1158/1078-0432.CCR-04-0429. Clin Cancer Res. 2004. PMID: 15448001

7

P63 expression in lung carcinoma: a tissue microarray study of 408 cases.

Au NH, Gown AM, Cheang M, Huntsman D, Yorida E, Elliott WM, Flint J, English J, Gilks CB, Grimes HL. Au NH, et al. Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):240-7. doi: 10.1097/00129039-200409000-00010. Appl Immunohistochem Mol Morphol. 2004. PMID: 15551738

8

Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.

Wiseman SM, Makretsov N, Nielsen TO, Gilks B, Yorida E, Cheang M, Turbin D, Gelmon K, Huntsman DG. Wiseman SM, et al. Among authors: huntsman dg. Cancer. 2005 May 1;103(9):1770-7. doi: 10.1002/cncr.20970. Cancer. 2005. PMID: 15770691 Free article.

9

Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma.

Lee CH, Huntsman DG, Cheang MC, Parker RL, Brown L, Hoskins P, Miller D, Gilks CB. Lee CH, et al. Among authors: huntsman dg. Int J Gynecol Pathol. 2005 Apr;24(2):147-52. doi: 10.1097/01.pgp.0000152026.39268.57. Int J Gynecol Pathol. 2005. PMID: 15782071

10

MDM2 protein expression is a negative prognostic marker in breast carcinoma.

Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB. Turbin DA, et al. Among authors: huntsman dg. Mod Pathol. 2006 Jan;19(1):69-74. doi: 10.1038/modpathol.3800484. Mod Pathol. 2006. PMID: 16258514 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

500 results

Search Page